Localisation of Prostaglandin F2,And E2 Binding
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
And NF-Κb-Dependent Mechanism
www.nature.com/scientificreports OPEN Prostaglandin I2 Attenuates Prostaglandin E2-Stimulated Expression of Interferon γ in a Received: 17 September 2015 Accepted: 11 January 2016 β-Amyloid Protein- and NF-κB- Published: 12 February 2016 Dependent Mechanism Pu Wang*, Pei-Pei Guan*, Xin Yu, Li-Chao Zhang, Ya-Nan Su & Zhan-You Wang Cyclooxygenase-2 (COX-2) has been recently identified as being involved in the pathogenesis of Alzheimer’s disease (AD). However, the role of an important COX-2 metabolic product, prostaglandin (PG) I2, in AD development remains unknown. Using mouse-derived astrocytes as well as APP/ PS1 transgenic mice as model systems, we firstly elucidated the mechanisms of interferonγ (IFNγ) regulation by PGE2 and PGI2. Specifically, PGE2 accumulation in astrocytes activated the ERK1/2 and NF-κB signaling pathways by phosphorylation, which resulted in IFNγ expression. In contrast, the administration of PGI2 attenuated the effects of PGE2 on stimulating the production of IFNγ via inhibiting the translocation of NF-κB from the cytosol to the nucleus. Due to these observations, we further studied these prostaglandins and found that both PGE2 and PGI2 increased Aβ1–42 levels. In detail, PGE2 induced IFNγ expression in an Aβ1–42-dependent manner, whereas PGI2-induced Aβ1–42 production did not alleviate cells from IFNγ inhibition by PGI2 treatment. More importantly, our data also revealed that not only Aβ1–42 oligomer but also fibrillar have the ability to induce the expression of IFNγ via stimulation of NF-κB nuclear translocation in astrocytes of APP/PS1 mice. The production of IFNγ finally accelerated the deposition of βA 1–42 in β-amyloid plaques. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Prostaglandin F2a Facilitates Hepatic Glucose Production Through Camkiig/P38/FOXO1 Signaling Pathway in Fasting and Obesity
1748 Diabetes Volume 67, September 2018 Prostaglandin F2a Facilitates Hepatic Glucose Production Through CaMKIIg/p38/FOXO1 Signaling Pathway in Fasting and Obesity Yuanyang Wang,1 Shuai Yan,2 Bing Xiao,2,3 Shengkai Zuo,2 Qianqian Zhang,2 Guilin Chen,1 Yu Yu,2,4 Di Chen,2,5 Qian Liu,1 Yi Liu,2 Yujun Shen,1 and Ying Yu1,2 Diabetes 2018;67:1748–1760 | https://doi.org/10.2337/db17-1521 Gluconeogenesis is drastically increased in patients Type 2 diabetes constitutes a major worldwide public health with type 2 diabetes and accounts for increased fasting burden and is expected to affect .642 million adults by plasma glucose concentrations. Circulating levels of 2040 (1). Type 2 diabetes is characterized by hyperglycemia, prostaglandin (PG) F2a are also markedly elevated in insulin resistance, and b-cell dysfunction, and often is diabetes; however, whether and how PGF2a regulates associated with low-grade chronic inflammation (2). Blood hepatic glucose metabolism remain unknown. Here, we glucose homeostasis is maintained by the balance between demonstrated that PGF2a receptor (F-prostanoid receptor hepatic glucose production (HGP) (glycogenolysis and glu- [FP]) was upregulated in the livers of mice upon fasting- coneogenesis) and glucose utilization by peripheral tissues. and diabetic stress. Hepatic deletion of the FP receptor In patients with type 2 diabetes, hepatic gluconeogenesis suppressed fasting-induced hepatic gluconeogenesis, is considerably elevated and contributes to both fasting whereas FP overexpression enhanced hepatic gluconeo- and postprandial hyperglycemia, and suppressing hepatic genesis in mice. FP activation promoted the expression gluconeogenesis improves insulin sensitivity and glucose METABOLISM of gluconeogenic enzymes (PEPCK and glucose-6- homeostasis, making it an attractive target for the treatment phosphatase) in hepatocytes in a FOXO1-dependent man- of diabetes (3). -
Effect of Prostanoids on Human Platelet Function: an Overview
International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1). -
Pharmaceuticals Appendix
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1 -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor, Gpr44 Amanda M
ORIGINAL ARTICLE Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis through the Receptor, Gpr44 Amanda M. Nelson1,5, Dorothy E. Loy2,5, John A. Lawson3,4, Adiya S. Katseff1, Garret A. FitzGerald3,4 and Luis A. Garza1 Prostaglandins (PGs) are key inflammatory mediators involved in wound healing and regulating hair growth; however, their role in skin regeneration after injury is unknown. Using wound-induced hair follicle neogenesis (WIHN) as a marker of skin regeneration, we hypothesized that PGD2 decreases follicle neogenesis. PGE2 and PGD2 were elevated early and late, respectively, during wound healing. The levels of WIHN, lipocalin-type prostaglandin D2 synthase (Ptgds), and its product PGD2 each varied significantly among background strains of mice after wounding, and all correlated such that the highest Ptgds and PGD2 levels were associated with the lowest amount of regeneration. In addition, an alternatively spliced transcript variant of Ptgds missing exon 3 correlated with high regeneration in mice. Exogenous application of PGD2 decreased WIHN in wild-type mice, and PGD2 receptor Gpr44-null mice showed increased WIHN compared with strain-matched control mice. Furthermore, Gpr44-null mice were resistant to PGD2-induced inhibition of follicle neogenesis. In all, these findings demonstrate that PGD2 inhibits hair follicle regeneration through the Gpr44 receptor and imply that inhibition of PGD2 production or Gpr44 signaling will promote skin regeneration. Journal of Investigative Dermatology (2013) 133, 881–889; doi:10.1038/jid.2012.398; published online 29 November 2012 INTRODUCTION successfully transition through all phases of the hair cycle, Scar formation and tissue regeneration are opposite results of and include associated structures, such as sebaceous glands the wound healing process. -
Use of Prostaglandins F2alpha and Analogues for the Healing of Corneal and Conjunctival Lesions
(19) & (11) EP 2 389 939 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 30.11.2011 Bulletin 2011/48 A61K 31/5575 (2006.01) A61K 9/00 (2006.01) A61K 47/18 (2006.01) A61P 27/06 (2006.01) (21) Application number: 10164376.5 (22) Date of filing: 28.05.2010 (84) Designated Contracting States: • Lallemand, Frédéric AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 94260 Fresnes (FR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Daull, Philippe PL PT RO SE SI SK SM TR 91450 Soisy-sur-Seine (FR) Designated Extension States: • Baudouin, Christophe BA ME RS 75016 Paris (FR) (71) Applicant: Novagali Pharma S.A. (74) Representative: de Mareüil-Villette, Caroline 91000 Evry (FR) Icosa 83, avenue Denfert-Rochereau (72) Inventors: 75014 Paris (FR) • Garrigue, Jean-Sébastien 91370 Verrières le Buisson (FR) (54) Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions (57) The invention relates to a composition for use surface and is free of deleterious preservative; the inven- in treating corneal and conjunctival lesions, wherein the tion also relates to a method for treating surface ocular composition comprises a prostaglandin F2alpha or ana- conditions in a patient in need thereof, comprising ad- logue, in a therapeutic amount, said composition being ministering a composition of the invention. in a form suitable for topical application on the ocular EP 2 389 939 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 389 939 A1 Description [Field] 5 [0001] The present invention relates to a solution for use in the treatment of corneal and conjunctival lesions. -
The EP2 Receptor Is the Predominant Prostanoid Receptor in the Human
110 BritishJournalofOphthalmology 1993; 77: 110-114 The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle Br J Ophthalmol: first published as 10.1136/bjo.77.2.110 on 1 February 1993. Downloaded from Toshihiko Matsuo, Max S Cynader Abstract IP prostanoid receptors, respectively. The EP Prostaglandins canreduce intraocularpressure receptor can be further classified into three by increasing uveoscleral outflow. We have subtypes, called EPI, EP2, and EP3 previously demonstrated that the human receptors.'89 The framework of the receptor ciliary muscle was a zone of concentration for classification has been supported in part, by binding sites (receptors) for prostaglandin F2a cloning and expression of cDNA for a human and for prostaglandin E2. Here, we try to thromboxane A2 receptor.20 elucidate the types of prostanoid receptors in It is important to know the types ofprostanoid the ciliary muscle using competitive ligand receptors located on the human ciliary muscle in binding studies in human eye sections and order to understand its role in uveoscleral out- computer assisted autoradiographic densito- flow, and to design new drugs with more potency metry. Saturation binding curves showed that and fewer adverse effects. In this study we tried the human ciliary muscle had a large number of to elucidate the type(s) of prostanoid receptors binding sites with a high affinity for prosta- located on the human ciliary muscle by glandin E2 compared with prostaglandin D2 combining receptor autoradiography with and F2,. The binding oftritiated prostaglandin competitive binding studies with various ligands E2 and F2a in the ciliary muscle was displaced on human eye sections. -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
Evidence Review D
National Institute for Health and Care Excellence Draft for consultation Intrapartum care for women with existing medical conditions or obstetric complications and their babies [D] Evidence reviews for asthma NICE guideline <TBC at publication> Evidence reviews for women at high risk of adverse outcomes for themselves and/or their baby because of existing maternal medical conditions September 2018 Draft for consultation Developed by the National Guideline Alliance hosted by the Royal College of Obstetricians and Gynaecologists DRAFT FOR CONSULTATION Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. -
The Roles of Prostaglandin F2 in Regulating the Expression of Matrix Metalloproteinase-12 Via an Insulin Growth Factor-2-Dependent Mechanism in Sheared Chondrocytes
Signal Transduction and Targeted Therapy www.nature.com/sigtrans ARTICLE OPEN The roles of prostaglandin F2 in regulating the expression of matrix metalloproteinase-12 via an insulin growth factor-2-dependent mechanism in sheared chondrocytes Pei-Pei Guan1, Wei-Yan Ding1 and Pu Wang 1 Osteoarthritis (OA) was recently identified as being regulated by the induction of cyclooxygenase-2 (COX-2) in response to high 12,14 fluid shear stress. Although the metabolic products of COX-2, including prostaglandin (PG)E2, 15-deoxy-Δ -PGJ2 (15d-PGJ2), and PGF2α, have been reported to be effective in regulating the occurrence and development of OA by activating matrix metalloproteinases (MMPs), the roles of PGF2α in OA are largely overlooked. Thus, we showed that high fluid shear stress induced the mRNA expression of MMP-12 via cyclic (c)AMP- and PGF2α-dependent signaling pathways. Specifically, we found that high fluid shear stress (20 dyn/cm2) significantly increased the expression of MMP-12 at 6 h ( > fivefold), which then slightly decreased until 48 h ( > threefold). In addition, shear stress enhanced the rapid synthesis of PGE2 and PGF2α, which generated synergistic effects on the expression of MMP-12 via EP2/EP3-, PGF2α receptor (FPR)-, cAMP- and insulin growth factor-2 (IGF-2)-dependent phosphatidylinositide 3-kinase (PI3-K)/protein kinase B (AKT), c-Jun N-terminal kinase (JNK)/c-Jun, and nuclear factor kappa-light- chain-enhancer of activated B cells (NF-κB)-activating pathways. Prolonged shear stress induced the synthesis of 15d-PGJ2, which is responsible for suppressing the high levels of MMP-12 at 48 h.